Faculty, Staff and Student Publications

Publication Date

1-1-2024

Journal

Nature Medicine

Abstract

The current third-line (and beyond) treatment options for RAS-mutant metastatic colorectal cancer have yielded limited efficacy. At the time of study start, the combination of sotorasib, a KRAS (Kirsten rat sarcoma viral oncogene homolog)-G12C inhibitor, and panitumumab, an epidermal growth factor receptor (EGFR) inhibitor, was hypothesized to overcome treatment-induced resistance. This phase 1b substudy of the CodeBreaK 101 master protocol evaluated sotorasib plus panitumumab in patients with chemotherapy-refractory KRAS

Keywords

Humans, Panitumumab, Proto-Oncogene Proteins p21(ras), Antibodies, Monoclonal, Colorectal Neoplasms, ErbB Receptors, Mutation, Antineoplastic Combined Chemotherapy Protocols, Piperazines, Pyridines, Pyrimidines

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.